Nordic Nanovector
Kjelsåsveien 168 B
Oslo
0884
Tel: 47-22-18-33-01
Fax: 47-22-58-00-07
Website: http://www.nordicnanovector.no/
Email: mail@nordicnanovector.no
343 articles about Nordic Nanovector
-
Nordic Nanovector to Present at DNB's 12th Nordic Healthcare Conference
12/8/2021
Nordic Nanovector announces that its CEO, Erik Skullerud will present a corporate overview via live webcast at DNB's 12th Nordic Healthcare Conference on 16 December 2021.
-
Nordic Nanovector to present at 3rd Targeted Radiopharmaceutical Summit 2021
12/7/2021
Nordic Nanovector ASA, a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases announces that its Chief Scientific Officer, Jostein Dahle, will give a presentation on 8 December at the 3rd Targeted Radiopharmaceutical Summit 2021 event.
-
Nordic Nanovector R&D Day: Building Value from Betalutin® and a pipeline of broader therapeutic opportunities targeting CD37
11/30/2021
Nordic Nanovector ASA, a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, will host an R&D day starting at 14:00 CET/ 13:00 GMT/ 08:00 ET.
-
Nordic Nanovector ASA: R&D Day to be virtual via live webcast only
11/29/2021
Nordic Nanovector ASA, a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the lives of patients with haematological cancers, provides an update on its planned R&D Day on Tuesday, 30 November 2021 starting at 14:00 CET/ 13:00 GMT/ 08:00 ET.
-
Nordic Nanovector ASA: Invitation to attend R&D Day
11/18/2021
Nordic Nanovector ASA, a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the lives of patients with haematological cancers, will host an R&D Day on Tuesday, 30 November 2021 starting at 14:00 CET/ 13:00 GMT/ 08:00 ET.
-
Correction: Nordic Nanovector ASA: Invitation to attend R&D Day - clarification of CMO title
11/18/2021
Nordic Nanovector ASA, a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the lives of patients with haematological cancers, will host an R&D Day on Tuesday, 30 November 2021 starting at 14:00 CET/ 13:00 GMT/ 08:00 ET.
-
Nordic Nanovector ASA: Results for the Third Quarter 2021
11/18/2021
Nordic Nanovector ASA announces its results for the third quarter 2021. A presentation by Nordic Nanovector's senior management team will be held in-person in Oslo and webcast live beginning at 8:30am CET - details below.
-
Nordic Nanovector ASA: Invitation to Third Quarter 2021 Results Presentation and Webcast
11/12/2021
Nordic Nanovector ASA announces that it will report its results for the third quarter 2021 on Thursday, 18 November 2021.
-
Nordic Nanovector supports The Health Policy Partnership's initiative to improve appropriate readiness for radioligand therapy (radioimmunotherapy) in lymphoma
11/9/2021
Nordic Nanovector supports The Health Policy Partnership's initiative to improve appropriate readiness for radioligand therapy (radioimmunotherapy) in lymphoma
-
Save the Date: Nordic Nanovector ASA to host in-person and virtual R&D Day on 30 November 2021
11/4/2021
Nordic Nanovector ASA, a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the lives of patients with haematological cancers, will host an R&D Day on Tuesday, 30 November 2021 at 14:00 CET/ 13:00 GMT/ 08:00 ET.
-
Nordic Nanovector enters research collaboration with the University of Pennsylvania to generate a novel CD37-targeting CAR-T cell approach
10/19/2021
Nordic Nanovector ASA is pleased to announce that it has entered into a research collaboration with the University of Pennsylvania to generate a CD37-targeting CAR-T cell approach as a potential treatment for patients with B-cell malignancies.
-
Nordic Nanovector ASA - allocation of PSUs - Sep 20, 2021
9/20/2021
The Board of Directors of Nordic Nanovector ASA has on 20 September 2021 decided to grant 350,000 Performance Share Units to the Company's new CEO and primary insider Mr. Erik Skullerud in accordance with the authorisation granted at the Annual General Meeting held on 28 April 2021.
-
Nordic Nanovector Appoints Experienced Pharmaceutical Business Leader Erik Skullerud as Chief Executive Officer
9/14/2021
Nordic Nanovector ASA (OSE: NANOV) announces the appointment of Erik Skullerud as Chief Executive Officer (CEO).
-
Nordic Nanovector ASA: Results for the Second Quarter and First Half 2021
8/27/2021
Nordic Nanovector ASA announces its results for the second quarter and first half 2021.
-
Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2021 Results Presentation Webcast
8/20/2021
Nordic Nanovector ASA announces that it will report its results for the second quarter and first half 2021 on Friday, 27 August 2021.
-
Nordic Nanovector Appoints Malene Brondberg as Interim Chief Executive Officer
7/1/2021
Nordic Nanovector ASA announces that Ms. Malene Brondberg has been appointed interim Chief Executive Officer with immediate effect.
-
Nordic Nanovector ASA: Share capital increase registered - June 22, 2021
6/22/2021
Reference is made to the stock exchange notice published on 18 June 2021, at 08:00 CEST, regarding a share capital increase in relation to current and former board members' exercise of in total 51,966 RSUs.
-
Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
6/22/2021
Nordic Nanovector ASA announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for stem cell transplantation.
-
Nordic Nanovector ASA: Increase of share capital - June 18, 2021
6/18/2021
The two US-based board members of Nordic Nanovector ASA, Joanna Horobin and Jean-Pierre Bizzari have resolved to settle a total number of 22,860 RSUs that were issued to them in June 2020 after they had elected to receive all or part of their remuneration for the period from the annual general meeting in 2020 to the annual general meeting in 2021 in RSUs.
-
Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors - June 18, 2021
6/18/2021
Reference is made to the stock exchange notice published 2 June 2021 regarding allocation of restricted stock units to members of the board of directors of Nordic Nanovector ASA.